Last reviewed · How we verify
NCT04741685
Clinical Efectivity of Two Different Sensor-augmented Pumps With Low Predictive Suspension Function
trial testing TTSX2 in Type 1 Diabetes in 23 participants. Completed in 10 June 2021.
1 June 2021
Quick facts
| Lead sponsor | Castilla-La Mancha Health Service |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 23 |
| Start date | 15 February 2021 |
| Primary completion | 1 June 2021 |
| Estimated completion | 10 June 2021 |
| Sites | 3 locations across Spain |
Drugs / interventions tested
- TTSX2
- MM640G
Conditions studied
- Type 1 Diabetes — all drugs for Type 1 Diabetes →
Sponsor
Castilla-La Mancha Health Service — full company profile →
Who can join
18 and older, any sex, with Type 1 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Observational cross-sectional multicenter study about effectiveness of two different sensor augmented-pumps with low glucose predictive function in Type 1 Diabetes Mellitus (T1DM) adult patients in routine clinical practice.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Real-world outcomes of two different sensor-augmented insulin pumps with predictive low glucose suspend function in type 1 diabetes patients.
Moreno-Fernandez J, Beato-Vibora P, Olvera P, Garcia-Seco JA, et al · · 2021 · cited 2× · PMID 34653567 · DOI 10.1016/j.diabres.2021.109093
Verify or expand the search:
- PubMed search for NCT04741685
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of TTSX2
Trials testing the same drug.
- NCT06834334 — Clinical Effectiveness of Advanced Hybrid Closed-loop Systems for Achieving Time in Tight Range Among T1D Patients · completed
Other recruiting trials for Type 1 Diabetes
Currently open trials in the same condition.
- NCT07061574 — A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New On · Phase 1, PHASE2 · recruiting
- NCT07360080 — Long-Term Outcomes of Teplizumab in Routine Clinical Care · recruiting
- NCT07457580 — Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) · recruiting
- NCT07212179 — Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 · NA · recruiting
- NCT07287943 — To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes. · NA · recruiting
Other Castilla-La Mancha Health Service trials
Trials by the same sponsor.
- NCT06834334 — Clinical Effectiveness of Advanced Hybrid Closed-loop Systems for Achieving Time in Tight Range Among T1D Patients · completed
- NCT06466967 — Clinical Utility of Tight Objectives of Advanced Hybrid Closed-loop Systems Among Type 1 Diabetes Patients (TightT1AHCL) · completed
- NCT06214780 — Effect of Heatwaves on Glycemic Control in People With Type 1 Diabetes Treated With Artificial Pancreas · completed
- NCT06222775 — Multicomponent Intervention on Lifestyle, Anthropometric Measurements, Glycemic Control and Quality of Life in Patients · NA · unknown
- NCT05918484 — Usefulness of Continuous Glucose Monitoring in MODY Diagnosis · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04741685 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Castilla-La Mancha Health Service
- Last refreshed: 11 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04741685.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing